<DOC>
	<DOCNO>NCT01177163</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacodynamic effect pharmacokinetic characteristic JNJ-28431754 multiple dosing patient Type 2 Diabetes Mellitus stable dose insulin .</brief_summary>
	<brief_title>A Safety , Tolerability , Pharmacokinetics , Pharmacodynamics Study JNJ-28431754 Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This randomize ( study drug assign chance ) , double-blind ( neither patient study doctor know name assign treatment ) , parallel-group ( group patient treat time ) determine safety , tolerability , pharmacokinetics ( PK ) ( drug absorb body , distribute within body remove body time ) pharmacodynamics ( PD ) ( action effect drug body ) oral ( take mouth ) dose JNJ 28431754 take twice daily compare placebo ( treatment identical appearance JNJ-2843174 contain active drug ) patient Type 2 Diabetes Mellitus ( T2DM ) receive therapy fixed-dose regimen insulin . Two group 14 patient study ; one group receive JNJ-2843174 ( 100 mg ) placebo daily 4 week group receive JNJ-2843174 ( 300 mg ) placebo twice daily 4 week . In 3 day immediately prior begin 4-week treatment period , patient take single oral dose placebo daily blood urine sample collect laboratory testing . During study , patient allow continue normal medication regimen insulin allow anti-diabetic medication . On select day study , patient require stay overnight study center study drug administer and/or blood urine sample collect laboratory testing . During study , patient experience worsen glycemia ( blood sugar ) , rescue therapy additional insulin type high dose may initiate Investigator medically appropriate . During study , patient monitor safety review adverse event result laboratory test , 12-lead electrocardiogram ( ECGs ) , vital sign measurement , body weight , physical examination , self-monitored blood glucose ( SMGB ) measurement . Unless otherwise specify , study drug take orally ( mouth ) overnight fast least 8 hour follow meal within 10 minute ; twice daily dose , even dose take prior even meal ( dinner ) . All patient take one placebo capsule daily 3 day immediately prior randomization . After randomization , patient take JNJ-28431754 ( 100 mg ) placebo daily JNJ-28431754 ( 300 mg ) placebo twice daily 4 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Have diagnose T2DM least 6 month prior study screen Be stable insulin regimen time screen Have stable weight ( ie , change 5 % 3 month prior screen ) Have glycosylated hemoglobin ( A1C ) &gt; =7 % &lt; =10.5 % study screen Have history Type 1 diabetes mellitus , secondary form diabetes , diabetic ketoacidosis , pancreas beta cell transplantation Have know history 2 severe hypoglycemic episode define protocol within past year Have history , currently active , significant illness determine Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Type 2 diabetes mellitus</keyword>
	<keyword>Canagliflozin</keyword>
	<keyword>JNJ-28431754</keyword>
	<keyword>Insulin</keyword>
	<keyword>Pharmacokinetic</keyword>
	<keyword>Pharmacodynamic</keyword>
	<keyword>SGLT-1</keyword>
</DOC>